Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study. by Walsh, SJ et al.
Intravascular Healing is not Affected by Approaches in Contemporary CTO 
PCI: The CONSISTENT CTO Study. 
Simon J Walsh MDa, Colm G Hanratty MDa, Margaret McEntegart MDb, Julian W Strange MDc, 
Johannes Rigger MDa, Peter A Henriksen MDd, Elliot J Smith MDe, Simon J Wilson MDa, Jonathan 
M Hill MDf, Zlatko Mehmedbegovic MDg, Bernard Chevalier MDh, Marie-Claude Morice MDh, 
James C Spratt MDi 
Running Title: CONSISTENT CTO Study 
Affiliations: 
aBelfast Health & Social Care Trust, Northern Ireland 
bGolden Jubilee Hospital, Glasgow, Scotland 
cBristol Heart Institute, England 
dRoyal Infirmary of Edinburgh, Scotland 
eSt Bartholemew’s Hospital, London, England 
fKing’s College Hospital, London, England 
gClinical Center of Serbia, Cardiology Clinic, Pasterova 2, 11 000 Belgrade 
hCardiovascular European Research Centre, 7 Rue du Théâtre, 91300 Massy, France 
iSt George’s University Hospital, London, England 
Address for Correspondence: 
Dr Simon Walsh, 






Word Count: 4398 
Funding: Unrestricted grant from Boston Scientific 
!1
Clinical Trial Registration: www.clinicaltrials.gov (NCT02227771) 
Conflict of Interest Statement: 
SJ Walsh - Consultant to and research funding from Abbott Vascular, Boston Scientific. Consultant 
to Medtronic and Teleflex 
CGH - Consultant to Abbott Vascular, Boston Scientific, Medtronic, Teleflex 
JWS - Consultant to Abbott Vascular,  proctor for and honoraria from Boston Scientific 
EJS - Proctor for and Honoraria from Boston Scientific 
JMH- Consultant to and research funding from Abbott Vascular, Abiomed, Boston Scientific, 
Medtronic, Shockwave Medical 
JCS - Consultant to Abbott Vascular, Boston Scientific, Teleflex 
All other authors - None declared 
All other authors - None declared 
Keywords: Percutaneous Coronary Intervention, Chronic Total Occlusion, Optical Coherence 
Tomography, Quality of Life 
Central Illustration: See separate file  
!2
Condensed Abstract (94 words)  
The adoption of dissection and re-entry techniques (DART) mean that success rates of >90% are 
achievable for unselected coronary chronic total occlusions (CTO). The impact of DART and sub-
intimal stenting on durability of CTO procedures are poorly understood.  A low rate of target vessel 
failure (TVF; composite of cardiac death, myocardial infarction related to the target vessel or any 
ischaemia-driven revascularisation) for CTO lesions occurred at 12 and 24 months. DART did not 
adversely affect intravascular healing assessed by Optical Coherence Tomography at 12 months or 
clinical events at 2 years. 
Clinical Perspectives 
This study confirms that high rates of success can be achieved for patients with complex CTO 
lesions with acceptable, low rates of complications. The durability of IVUS-guided CTO PCI using 
contemporary techniques employing dissection and re-entry techniques (DART) in addition to sub-
intimal stenting is confirmed at 12 and 24 months. DART does not adversely affect intravascular 
healing at 12 months when assessed by intravascular imaging. Indeed, similar healing is noted 
within stents sited inside the previous lumen as with those where a sub-intimal course was 
confirmed on IVUS before stent deployment. Longer term clinical and intravascular outcomes are 
still required for these complex patients. 
Twitter content 
IVUS adjudicated sub-intimal passage does not affect clinical, angiographic or OCT outcomes at 1 
year @JACCjournals #CONSISTENTCTO  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Abstract (250 words) 
Objectives 
To provide angiographic, imaging and clinical outcomes following chronic total occlusion (CTO) 
percutaneous coronary intervention (PCI) with dissection and re-entry techniques (DART) and sub-
intimal (SI) stenting compared to intimal techniques.  
Background 
Reliable procedural success and safety in CTO PCI requires the use of DART to treat the most 
complex patients. Potential concerns regarding the durability of DART with SI stenting still need to 
be addressed. 
Methods 
This was a prospective, multi-centre, single-arm trial of patients with an appropriate indication for 
CTO PCI. 
Results 
Successful CTO PCI was performed in 210/231 patients (91% success). At 1-year, the primary 
endpoint of target vessel failure (cardiac death, myocardial infarction related to the target vessel or 
any ischaemia-driven revascularisation) occurred in 5.7% of patients, meeting the pre-set 
performance goal. Major adverse cardiovascular events (MACE; all-cause mortality, myocardial 
infarction or target vessel revascularisation) occurred in 10% at 1-year and 17% by 2-years and was 
not influenced by DART. Quality of life measures significantly improved from baseline to 12-
months. There was no difference in intravascular healing assessed by optical coherence tomography 
(OCT) at 12-months for patients treated with DART and sub-intimal stenting compared to intimal 
strategies. 
Conclusions 
Contemporary CTO PCI is associated with medium-term clinical outcomes comparable to other 
complex PCI cohorts, and significant improvements in quality of life. The use of DART with sub-




ADR - Antegrade dissection and re-entry 
AWE - Antegrade wire escalation 
BP - Bio-absorbable Polymer 
CONSISTENT - Conventional Antegrade versus Sub-Intimal Synergy Stenting in Chronic Total 
Occlusions 
DART - Dissection and re-entry technique 
DP - Durable Polymer 
EES - Everolimus Eluting Stent 
JCTO - Japanese chronic total occlusion  
RDR - Retrograde dissection and re-entry 
RWE - Retrograde wiring 
!5
Introduction 
Whilst chronic total occlusions (CTO) in the coronary circulation remain the most challenging 
lesions to treat by percutaneous coronary intervention (PCI), there has been a considerable 
evolution in techniques and technologies. The adoption of systematic and algorithm-based 
approaches [1] has resulted in technical success rates approaching 90% in unselected patients. [2-4] 
Although antegrade wire techniques are predictably successful in less complex occlusions, 
dissection re-entry techniques (DART) are required to treat patients with more complex disease. 
[2-4] Despite this, comparatively little data exists to support their durability. Concerns have also 
been expressed based on the poor outcomes of sub-intimal tracking and re-entry (STAR) in CTO 
lesions, [5,6] and similar questions have been raised regarding sub-intimal stent deployment when a 
retrograde approach is required. [7] 
Contemporary CTO PCI approaches have distinct technical differences to historical practice and 
good medium-term clinical outcomes have been described in larger clinical registries irrespective of 
approach taken, the presence or absence of dissection within the vessel, or requirement for sub-
intimal stenting. [8-10]  
Intravascular ultrasound (IVUS) following lesion crossing has illustrated a discordance between the 
presumed vs actual mode of lesion crossing (sub-intimal vs intimal). [11] As such, any previous 
assumptions regarding the impact of these approaches and assumed sub-intimal stent deployment in 
the absence of intravascular imaging are likely to be flawed. The longer term implications of DART 
are also incompletely understood, although smaller studies have suggested a potential for adverse 
intravascular healing at shorter follow-up intervals when DART are applied. [12,13] 
The CONSISTENT study aimed to understand the impact of DART on procedural durability as 
assessed by clinical or imaging parameters. 
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Methods 
This was a single-arm, investigator-led, prospective, multi-centre trial with patient recruitment 
undertaken in 6 centres in the United Kingdom. The trial was administered and overseen by a 
Clinical Research Organization (Cardiovascular European Research Center; CERC) and the data 
were overseen, assessed, and adjudicated by a Clinical Events Committee, angiographic core 
laboratory, intravascular ultrasound (IVUS) core laboratory, optical coherence tomography (OCT) 
core laboratory and Data and Safety Monitoring Board. The study protocol was approved by the 
relevant authorities in each centre and there was compliance with the Declaration of Helsinki. All 
patients provided written, informed consent prior to trial participation. The research was funded by 
an unrestricted grant from Boston Scientific who had no oversight or input on data gathering, data 
interpretation or this manuscript. The trial was registered on clinicaltrials.gov (NCT02227771). 
Recruitment commenced in December 2014 and was completed in December 2016. The 
angiography and OCT core-lab was at CERC and the IVUS core-lab was in Belfast. 
Once the inclusion and exclusion criteria (Appendix 1) were fulfilled and informed consent had 
been provided, the patient completed pre-PCI quality of life assessments before planned CTO PCI. 
This study stent was a 3rd generation Everolimus eluting stent with a bio-absorbable polymer (EES-
BP). [14] (Synergy stent Boston Scientific, Marlborough, MA, USA). After the lesion was 
successfully crossed and EES-BP stents were implanted, the patient was considered included in the 
study. A detailed description of the procedures is also outlined in Appendix 1.  
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Study Endpoints 
The primary device related endpoint was the 12-month target vessel failure (TVF) rate, defined as a 
composite of cardiac death, myocardial infarction (MI; Q-wave and non–Q-wave) related to the 
target vessel or ischaemia-driven revascularization of the target vessel. 
Cardiac death was defined as death due to any of the following: acute MI, cardiac perforation/
pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident (CVA) 
through hospital discharge or CVA suspected of being related to the procedure, death due to any 
complication of the procedure or any death in which a cardiac cause could not be excluded. MI was 
defined according to the third universal definition. [15] Target vessel revascularisation (TVR) was 
any ischaemia-driven repeat percutaneous intervention to improve blood flow in the successfully 
treated target vessel or bypass surgery of the target vessel. A TVR was considered as ischaemia-
driven if the target vessel diameter stenosis was ≥50% by quantitative coronary analysis and there 
was presence of clinical or functional ischaemia which could not be explained by other coronary or 
graft lesions. Definite, probable or possible stent thrombosis were defined according to Academic 
Research Consortium (ARC) criteria. [16]  
In contrast to studies of non-CTO lesions, a scheduled angiogram and/or resultant lesion 
optimisation (i.e. not ischaemia driven) within 12 weeks of the CTO PCI did not represent an 
adverse event according to the protocol. In the experience of the investigators these procedures are 
often required to allow complete revascularisation and/or optimisation of the index PCI result. This 
approach is consistent with the recent ARC-2 white paper that recognises the need for repeat 
procedures in complex lesions and the relevance of clinically and functionally indicated TVR as an 
adverse endpoint as opposed to protocol-allowed planned procedures. [17]. The procedural result 





A total of 231 patients were admitted to hospital for a clinically indicated CTO PCI and provided 
informed consent to be enrolled if a successful CTO PCI was undertaken. Subsequently, 210 
patients had a successful procedure (91% of attempted cases) and were included in the study. 
Patient flow through the study is outlined in Figure 1. Baseline demographics are described in 
Supplementary Table 1. The mean age was 63.5, 81.4% were male and 48.6% had normal left 
ventricular function. In total 21% were diabetic, 18.1% had prior CABG, 72.9% had single vessel 
disease with the majority of lesions in the right coronary artery (61.9%). 
Procedural characteristics are outlined in Supplementary Table 2. The CTO lesions were complex 
(mean JCTO score 2.4) and long (mean occlusion length 29mm) with a mean stent length of 
85.6mm implanted per patient. Dual catheter access was used in 78.6% of cases. Procedural 
strategies are outlined in the online Appendix. The final successful strategy was antegrade wire 
escalation (AWE) in 72/210 (34.3%), retrograde wire escalation (RWE) in 37/210 (17.6%), 
antegrade dissection re-entry (ADR) in 38/210 (18.1%) and retrograde dissection re-entry (RDR) in 
63/210 (30%). This led to an expectation of intimal wire-based tracking in 51.9% and blunt 
dissection with sub-intimal tracking in 48.1%. The overall procedural complication rate was low 
(Supplementary Table 2). 
Pre-stent IVUS was available in 190/210 (90.5%) patients. Core-lab analysis demonstrated 
discordance between presumed and actual equipment passage in 15.8% (Figure 2).   
A per protocol, a plan for an early angiogram +/- PCI could be declared on the e-CRF after the CTO 
was successfully opened at the index procedure. This allowed for non-target vessel PCI as well as 
optimisation of the target lesion. A total of 40/210 (19.1%) patients had a protocol allowed early 
procedure, of whom 18 had angiography alone.  Seven patients had non-target vessel PCI and 1 had 
SVG closure alone. A total of 5 patients had target vessel stenting for distal disease, of whom 1 also 
had a non-target vessel PCI and 1 also had planned SVG closure. Finally, 9 patients had POBA only 
of the target vessel to manage positive remodelling within the stented segment. Therefore, 14/210 
(6.7%) had a protocol allowed, scheduled early target vessel intervention. These were short 
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procedures (procedure time 51.1 minutes ± 31.8, fluoroscopy time 10.9 minutes ± 10.5), had low 
radiation doses (3371 cGycm2 ± 4498) and were not associated with complications. 
Follow-up rates were high. A total of 3 patients withdrew consent. Clinical follow-up was available 
in 206/207 (99.5%) at 12 and 24-months with angiographic and OCT follow-up in 188/207 (90.8%) 
and 175/207 (84.5%) at 12-months respectively.  
The primary endpoint of TVF occurred in 12/210 (5.7%) by 12-months. This was adjusted 
subsequent to initial reporting after adjudication of a single MI event by the clinical events 
committee. There were 0 cardiac deaths by 12-months. Total mortality was 3 (1.4%). Any MI 
occurred in 3 patients in-hospital and 5 patients (1.9%) at 1 year. In total, 15/210 (7.1%) TVR 
events occurred by 12-months. The MACE rate (all-cause mortality, MI or TVR) was 10% at 12-
months. Definite/probable stent thrombosis occurred in 4/210 patients (1.9%) by 12-months. Sub-
group analysis and outcomes for patients treated according to technique and diabetic status are 
presented in Table 1. A multivariable analysis did not demonstrate any significant association 
between strategy employed and TVF (p=0.893) at 12-months.  
Quality of life assessments were performed using the Seattle Angina Questionnaire (SAQ) and 
EQ5D questionnaire at baseline and 12 months. Outcomes are presented in Figure 3 and 
Supplementary Table 3.  
Angiographic follow-up was performed in 188 patients at 12 months. Full QCA analysis was 
available from 179 patients. Binary angiographic restenosis (in-segment), as defined by QCA, 
occurred in 26/179 patients (14.5%). Re-occlusion of the target vessel in the absence of a clinical 
event was noted in 6/179 patients (3.4%). The mean in-segment minimum lumen diameter gain was 
1.86mm (±0.6) with a mean late loss of 0.14mm (±0.6).  
OCT was performed in 175 patients at 12 months (case example Figure 4). Full analysis was 
available from 167 cases with >449,000 struts assessed (Table 2). The frequency of malpapposed 
struts per lesion was 2.5% (±4.7). The frequency of covered struts per lesion was 91.1% (±9.8). 
Aneurysm formation was noted in 11 patients (6.6%), of which 5 were associated with intra-plaque 
equipment tracking. Outcomes according to the application of DART and / or the presence of IVUS 
confirmed dissection at index procedure are also presented in Table 2. 
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By 24-months, TVF had occurred in 10% with no additional MIs. Only 1 cardiac death had 
occurred with 9 (4.3%) deaths in total.  TVR was noted in 25/210 (11.9%), with an overall MACE 
rate of 17% and definite or probable stent thrombosis occurred in 6/210 (2.9%). 
!11
Discussion 
Procedural and Clinical Outcomes 
Despite lesion complexity, it is now possible to recanalise ~90% of CTO lesions, with the 91% 
success demonstrated within this study similar to other contemporary series. [2-4, 21, 22] 
CONSISTENT maintained procedural outcomes in patients with high lesion complexity (mean 
JCTO score of 2.4), using similar contrast doses but lower radiation exposure than other recent 
studies. [4, 22, 23] This also did not occur at the expense of increased complication rates 
(Supplementary Table 2). [4, 22, 23] 
Latest generation DES platforms have improved clinical outcomes for patients across the full 
spectrum of coronary intervention. Our finding of a TVF rate of 5.7% at 1 year using an EES-BP 
stent met the initial performance goal (TVF <15%). MACE in CONSISTENT was 10% at 12-
months and is similar to the protocol defined MACE noted in EXPERT CTO (10%) [24] at the same 
time point, where durable polymer (DP) EES were studied. Indeed the 1-year MACE rates for 
CONSISTENT are similar to that reported in multi-vessel non-occlusive disease [21] and in elderly 
patients where the same stent was used. [25] The 2-year TVF and 2-year MACE rates are also in 
line with what would be expected for a complex patient group with advanced, but non-occlusive 
coronary disease. 
DART and/or sub-intimal stenting are required to successfully revascularise the most complex CTO 
lesions. [2, 3, 26] DART are described in 40-49% of almost 7,000 cases in registries across 
numerous geographies. [2,4, 26, 27] CONSISTENT mirrored this practice, with the DART sub-
group having more complex lesions and a higher disease burden (Table 1). As such, longer stent 
lengths were required to treat these patients (97mm vs 75mm). This increase in stent length was 
associated with a non-significant increase in TVR, but not death (only 1 cardiac death occurred in 
this study) or MI at 2 years. In keeping with broader PCI studies, the presence of Diabetes remained 
the strongest predictor of MACE and TVR (Table 1) at both 12 and 24-months. 
Similar to OPEN-CTO, [4] patients included in the CONSISTENT study were highly symptomatic 
at baseline despite medical therapy, and demonstrated significant gains across a range of quality of 
life measures. This finding stands in contrast to recent randomised studies in CTO PCI, [22, 23] 
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where symptomatic patients likely defaulted to revascularisation rather than study enrolment (and 
potential randomisation to medical therapy), thus blunting any potential symptomatic benefits. 
CONSISTENT confirms that when symptomatic patients undergo successful CTO PCI they can 
expect an improved health status 12-months beyond a procedure.  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Imaging and Intravascular Healing 
  
Angiographic follow-up showed that re-occlusion was infrequent (3.4%) and similar to that 
reported at 9 months in the PRISON IV study (1.8%; 5/281) where less complex lesions also 
underwent core-laboratory angiographic follow-up. [28] Binary angiographic restenosis at 12-
months (14.5%) was comparable to contemporary rates described in EES treated bifurcation lesions 
at 9-months (10.5%). [29] These results stand in contrast to the smaller ACE-CTO study (n=89 with 
angiographic follow up) [30] that reported a very high rate of restenosis (46%) and TVR (39% 
versus 7.1%) at 12-months.  
Intravascular healing for EES-BP stents, as assessed by OCT strut coverage, is high in shorter, non-
occlusive lesions (Table 3). [31, 32] One small series has suggested that healing in CTO lesions 
may be delayed compared to non-occlusive disease. [33] Data for strut coverage in CTO lesions are 
limited to small series [12, 13, 34] where DART have been associated with poor intravascular 
healing. [12, 13] 
The CONSISTENT imaging sub-group represents the largest post-PCI OCT follow up in the 
literature with an almost ten-fold higher number of struts (449,130) analysed compared to previous 
CTO PCI investigations (Supplementary Table 4).  No meaningful difference in vessel healing at 
12-months was demonstrated between DART and intimal wiring (n=167, DART = 79, IVUS 
confirmed dissection = 73). This may have been helped by the use of IVUS at the index procedure 
to confirm the intravascular course and inform subsequent stenting. [21] The overall rates of strut 
coverage (91.1%), malapposed struts (2.5%) and uncovered struts (6.4%) are reassuring. Although 
the use of protocol defined optimisation may also contribute, only a small number of patients 
(6.7%) had an early protocol allowed intervention on the target vessel. 
Aneurysm formation occurred in 11 (6.6%) of cases, less than ACE-CTO. [12] No patients had 
extension of antiplatelet therapy as a result of these findings. The mechanism or even definition of 
aneurysm vs pseudoaneursym is ill-defined, but it is unsurprising to note that 5/11 occurred in 
patients with lumen-based revascularisation. Positive remodelling after CTO PCI occurs 
irrespective of DART and may be dramatic. Later acquired malapposition may be a result of ‘re-
pressurisation’ of the vascular bed leading to ‘demand-driven’ vessel expansion. Of the 11 patients 
with aneurysm in CONSISTENT, 3 clinical events occurred in 2 patients. One had a peri-procedural 
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type 4a MI that was unrelated to the aneurysm noted 12-months later. A second patient had a non-
ischaemia driven TVR at scheduled angiographic follow-up and suffered a non-cardiac death 625 
days post-procedure. No patients who had an early optimisation procedure for the target vessel 
(n=14) presented with an aneurysm at 12-months. 
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Limitations 
The main limitations of the study are that the cases were not randomised to a placebo arm (i.e. sham 
procedure), nor was there an optimal medical therapy only arm. The procedures were carried out by 
experienced PCI operators, all of whom have performed >1000 CTO PCI procedures and are 
familiar with all of the described approaches. Some patients were lost to angiographic follow-up 
(9.2%) and different stents were not assessed in this study. These results may not be replicated by 
operators or centres with less experience of these techniques. 
Conclusions 
Successful safe CTO PCI is now feasible for the majority of patients. The use of a latest generation 
EES-BP stent is safe and effective in contemporary CTO PCI. Successful revascularisation is 
associated with durable, highly significant gains in quality of life at 12-months. TVF rates are low 
at 12 and 24-months, with MACE rates comparable to other complex patient groups. 
The application of DART, and/or sub-intimal stenting facilitates CTO PCI success rates of >90% to 
be achieved safely despite complex anatomy. Operators may be incorrect on assumed intimal or 
sub-intimal tracking in 1-in-6 cases. There was no difference in 12-month intravascular healing 
assessed by OCT, regardless of crossing technique or sub-intimal stenting. Although the 12-month 
TVR was higher following DART, after multivariable adjustment crossing strategy was not an 
independent predictor of TVF. Furthermore, there was no significant difference in TVR at 24-
months. Disease burden and the presence of Diabetes are the main predictors of both TVR and 
MACE. Cardiologists should be reassured that modern CTO PCI techniques can be safely applied 
when indicated.  
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Figure Legends 
Figure 1. Patient flow through the study. 
CTO; chronic total occlusion, PCI; percutaneous coronary intervention, IVUS; intravascular 
ultrasound, OCT; optical coherence tomography 
Figure 2.  Discordance between presumed and core laboratory IVUS-confirmed recanalisation path. 
Presumed course is intimal plaque for antegrade and retrograde wire escalation and sub-intimal for 
antegrade and retrograde dissection and re-entry. 
ADR; antegrade dissection and re-entry, AWE; antegrade wire escalation, RDR; retrograde 
dissection and re-entry, RWE; retrograde wire escalation 
Figure 3.  Seattle Angina Questionnaire at baseline and 12 months. 
SAQ; Seattle Angina Questionnaire, PL; physical limitation, AS; angina stability, AF; angina 
frequency, TS; treatment satisfaction, DP; disease perception. Data presented are mean values. 
Figure 4. Example of a long LAD CTO before and after PCI, with 12-month follow-up. 
Panel A: Baseline angiogram demonstrating a long CTO and Stingray balloon in position for re-
entry. Panel B: Acute result after completion of PCI. Panel C: Fluoroscopic image demonstrating 
extent of stenting at 12-month angiography. Panel D: Corresponding 12-month angiogram. Panel E: 
OCT image at 12-months demonstrating vascular healing at the re-entry zone. 
!21
Figure 1. Patient flow through the study. 
CTO; chronic total occlusion, PCI; percutaneous coronary intervention, IVUS; intravascular 
ultrasound, OCT; optical coherence tomography  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Figure 2.  Discordance between presumed and core laboratory IVUS-confirmed recanalisation path. 
Presumed course is intimal plaque for antegrade and retrograde wire escalation and sub-intimal for 
antegrade and retrograde dissection and re-entry. 
ADR; antegrade dissection and re-entry, AWE; antegrade wire escalation, RDR; retrograde 
dissection and re-entry, RWE; retrograde wire escalation 
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Figure 3. Seattle Angina Questionnaire at baseline and 12 months. 
SAQ; Seattle Angina Questionnaire, PL; physical limitation, AS; angina stability, AF; angina 
frequency, TS; treatment satisfaction, DP; disease perception. Data presented are mean values. 
!24
Figure 4. Example of a long LAD CTO before and after PCI, with 12-month follow-up.  
Panel A: Baseline angiogram demonstrating a long CTO and Stingray balloon in position for re-
entry. Panel B: Acute result after completion of PCI. Panel C: Fluoroscopic image demonstrating 
extent of stenting at 12-month angiography. Panel D: Corresponding 12-month angiogram. Panel E: 
OCT image at 12-months demonstrating vascular healing at the re-entry zone. 
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Table 1. One and 2-year outcomes according to CTO PCI final approach and Diabetic Status 
DART; dissection and re-entry technique, SD; standard deviation, CABG; coronary artery bypass 
grafting, JCTO; Japanese chronic total occlusion, TVF; target vessel failure, MACE; major adverse 








Diabetes   
N = 44 P-value
Lesion Length (mm) N (SD) 36.3 (22.0) 22.6 (16.6) <0.0001
Prior CABG Target Vessel N (%) 22 (21.8) 11 (10.1) 0.023
JCTO Score Mean (SD) 2.9 (1.2) 2.0 (1.1) <0.0001
Stent Length (mm) Mean (SD) 96.6 (31.6) 75.4 (31.4) <0.0001
MACE at 12 months N (%) 14 (13.9) 7 (6.4) 0.073
MACE at 24 months N (%) 21 (20.8) 15 (13.8) 0.177
TVR at 12 months N (%) 11 (10.9) 4 (3.7) 0.042
TVR at 24 months N (%) 15 (14.9) 10 (9.2) 0.204
MACE at 12 months N (%) 11 (6.6) 10 (22.7) 0.004
MACE at 24 months N (%) 20 (12.5) 16 (36.3) 0.0001
TVR at 12 months N (%) 8 (4.8) 7 (15.9) 0.02
TVR at 24 months N (%) 13 (7.8) 12 (27.3) 0.0004
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Table 2. OCT findings for the study population, according to procedural approach and pre-stenting 
IVUS evidence of dissection or not. 
DART; dissection and re-entry technique, IVUS; intravascular ultrasound, Min; minimum, Max; 
maximum, CS; cross section. 
Variable Statistic Result
Result Result Result Result











Struts Analysed per 
Segment












Min Diameter (mm) Mean (SD) 3.1 (0.7) 3.1 (0.6) 3.0 (0.7) 0.327 3.1 (0.7) 3.0 (0.7) 0.327
Max Diameter (mm) Mean (SD) 3.7 (0.7) 3.8 (0.7) 3.6 (0.7) 0.068 3.8 (0.7) 3.6 (0.7) 0.068
Distal Reference
Min Diameter (mm) Mean (SD) 2.5 (1.3) 2.5 (0.6) 2.4 (0.5) 0.244 2.5 (0.6) 2.4 (0.5) 0.244
Max Diameter (mm) Mean (SD) 2.9 (1.7) 3.1 (0.7) 2.8 (0.6) 0.003 3.0 (0.7) 2.9 (0.7) 0.362
In-stent CS Area (mm2) Mean (SD) 8.2 (2.5) 8.6 (2.7) 7.9 (2.2) 0.068 8.6 (2.5) 7.8 (2.4) 0.038
Neo-Intimal Hyperplasia 
Area at Maximal 
Obstruction (mm2)
Mean (SD) 1.8 (1.3) 1.9 (1.4) 1.7 (1.1) 0.305 1.9 (1.4) 1.7 (1.2) 0.324
Neo-Intimal Hyperplasia 
Area (mm2)
Mean (SD) 1.3 (0.7) 1.4 (0.7) 1.3 (0.6) 0.323 1.4 (0.7) 1.3 (0.6) 0.324
Neo-Intimal Obstruction 
(%)
Mean (SD) 16.9 (8.0) 16.3 (8.1) 17.4 (7.9) 0.377 17.1 (8.3) 16.7 (7.8) 0.750
Stent Area Stenosis (%) Mean (SD) 31.1 (15.3) 31.8 (16.0) 30.4 (14.6) 0.556 32.2 (15.1) 30.1 (15.5) 0.382
Frequency of Covered 
Struts per Lesion (%)
Mean (SD) 91.1 (9.8) 90.1 (10.0) 91.9 (9.6) 0.238 91.3 (10.0) 90.8 (9.8) 0.747
Frequency of Uncovered 
Struts per Lesion (%)
Mean (SD) 6.4 (6.4) 7.0 (6.6) 5.9 (6.1) 0.226 6.4 (7.0) 6.4 (5.8) 1
Maximum Consecutive 
Length of Uncovered Struts 
(mm)
Mean (SD) 1.9 (1.9) 2.1 (2.0) 1.8 (1.8) 0.311 1.9 (1.8) 2.0 (2.0) 0.739
Maximum 13.2 10.0 13.2 9.6 13.2
Frequency of Malapposed 
Struts per Lesion (%)
Mean (SD) 2.5 (4.7) 2.9 (4.7) 2.2 (4.6) 0.334 2.3 (3.9) 2.8 (5.2) 0.495
Maximum Consecutive 
Length of Malapposed 
Struts (mm)
Mean (SD) 1.2 (1.7) 1.4 (1.9) 1.0 (1.6) 0.143 1.2 (1.5) 1.2 (1.9) 1
Maximum 9.6 9.6 8.7 7.9 9.6
Persistent Dissection In-
stent
N (%) 6 (3.6) 4 (5.1) 2 (2.3) 0.425 1 (1.4) 5 (5.4) 0.231
Aneurysm Formation N (%) 11 (6.6) 8 (10.1) 3 (3.4) 0.119 6 (8.2) 5 (5.4) 0.538
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